Core Viewpoint - Shanghai Yamei Biological Technology Co., Ltd. has signed a contract to settle in the Qizhi Dao Innovation Space, accelerating its technological innovation and industrial upgrading process, while maintaining a leading position in the domestic protein immunoblotting market with market shares of 21.05% in 2023 and 26.76% in 2024 [1][4]. Company Overview - Established in March 2019, Yamei Biological focuses on the research and production of life science research tools, aiming to reduce reliance on imported protein immunoblotting reagents in China [2]. - The product range includes antibodies, ELISA kits, molecular enzymes, protein reagents, and cell biology products, providing comprehensive solutions in the protein immunoblotting field [2]. Research and Development - The company has invested in a 600 square meter reagent R&D center in Minhang District and a 2000 square meter antibody and ELISA kit R&D center in Caohejing High-tech Park, enhancing its technical system and application research capabilities [2]. - A production base of 4600 square meters has been established in Tongling, Anhui, equipped with a 600 square meter GMP-standardized workshop to ensure quality control and large-scale production [2]. Market Expansion - Since its product launch in 2019, Yamei Biological has introduced hundreds of research tool products, entering thousands of laboratories in hospitals, universities, research institutes, and pharmaceutical companies [3]. - In 2024, the company established Yamei Bio LLC in San Diego, USA, and Hong Kong Yamei to expand its global business and cover the Southeast Asian market [3]. Technological Breakthroughs - Yamei Biological achieved a key technological breakthrough in the field of hemocyanin reagents, developing a high-purity extraction technology for shrimp hemocyanin (SHC) that achieves over 98% purity [3]. - The production cost of SHC is approximately 50% lower than traditional KLH, with superior performance in immunogenicity, solubility, and thermal stability [3][4]. Industry Impact - The company has successfully replaced Thermo Fisher's KLH products, breaking a 20-year market dominance by foreign companies in the hemocyanin reagent field, thus reducing R&D and production costs for domestic research institutions and biopharmaceutical companies [4]. - Yamei Biological's sales revenue has shown continuous growth, reaching 58.5868 million yuan in 2024, with its main products supporting prestigious institutions like Peking University and Tsinghua University [4]. Future Outlook - By joining the Qizhi Dao Innovation Space, Yamei Biological aims to leverage advanced industrial data and technology resources to enhance product competitiveness and expand market opportunities [5]. - The company is committed to becoming a leading supplier of life science products through continuous technological innovation and promoting the localization of research and medical reagent products [5][6].